Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ginkgolide K
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Ginkgolide K is a natural terpene trilactone isolated from the leaves of Ginkgo biloba. It acts as a potent antagonist of the platelet-activating factor (PAF) receptor and exhibits significant neuroprotective and cardioprotective properties. Preclinical studies suggest that ginkgolide K protects against acute ischemic stroke and cardiac ischemic injury by inducing protective autophagy via the AMPK/mTOR/ULK1 signaling pathway and mitigating endoplasmic reticulum stress through the IRE1α/XBP1 pathway. It is primarily utilized as a research-use-only compound and is not currently approved for clinical use as a standalone therapeutic.
- Other names
- GKGinkgolide K
02
Targets
PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on ginkgolide K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ginkgolide K.